Successful Acquisitions

JUNE 27, 2023

The past 18 months have marked the slowest initial public offering market since the financial crisis of 2008. There are many reasons many American companies are so hesitant to go public. Some have gotten capital from other sources like private equity, family offices, unsecured lending sources, or even friends and family.

IPO 111

IPO Initial Public Offering Public Trading Private Equity 111

OfficeHours

JUNE 5, 2023

Optimal Capital Structure Designing an optimal capital structure is critical to the success of a paper LBO. Balancing debt and equity components are crucial to minimizing the cost of capital while maintaining financial flexibility. Remember, this is private equity, NOT angel investing.

Private Equity 147

Private Equity Valuation Equities Debt 147

Software Equity Group

MARCH 21, 2023

There are several resources for growth capital: debt from a lender or financial institution, minority equity financing, or majority equity financing through a control transaction. You can also sell debt instruments such as bonds, bills, or notes to investors to raise capital.

Finance 52

Finance Finance Debt Equities 52

Peak Frameworks

SEPTEMBER 19, 2023

Airbnb initially bootstrapped their venture, but as their idea gained traction, they attracted funding from Y Combinator, a renowned startup accelerator, marking their official entry into the world of venture capital. Private equity firms can step in, providing the needed capital and expertise to restructure and revamp the business.

Business 52

Business Finance Finance Private Equity 52

Cooley M&A

JANUARY 30, 2024

3] Elliott Management (15 campaigns), Starboard Value (9), Align Partners (8), ValueAct Capital (8) and Ancora (6) topped the activist leaderboard for the year, with JANA Partners and Sarissa Capital Management also highly active in the technology and healthcare sectors. [4]

Private Equity 52

Private Equity M&A Capital Investors 52

Cooley M&A

JANUARY 25, 2023

Will 2023 see a resurgence of traditional public M&A deals or will macro factors and the looming threat of regulatory review continue to push biotechnology companies down creative paths? It’s a more challenging market environment right now than we’ve seen in many years,” said Charlie Kim , who co-chairs Cooley’s capital markets practice.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

In an environment where licensing deals also present antitrust risk, big pharmaceutical companies may favor M&A instead to have full control over the assets – and make the cost of litigating against the antitrust agencies worth the time and money. What’s next?

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52